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Abstract: Biocatalysts provide an efficient, inexpensive, and
environmentally friendly alternative to traditional organic
synthesis, especially for compounds with complex
stereochemistries. The past decade has seen a significant rise
in the use of biocatalysts for the synthesis of compounds in an
industrial setting; however the incorporation of single
enzymatically catalyzed steps into organic synthesis schemes
can be problematic. The emerging field of synthetic biology has
sparked interest in the development of whole-cell factories that
can convert simple, common metabolites into complex,
high-value molecules with a range of applications such as
pharmaceuticals and biofuels. This review summarises
conventional methods and recent advances in metabolic
engineering of pathways in microorganisms for the synthesis of
natural products.
1. Beginnings of metabolic engineering
Synthetic biology integrates two closely related disciplines -
biochemistry and genetic engineering - to artificially design and
manipulate biological systems in organisms with the aim of
remodelling their metabolic pathways to change their function
and behaviours.[1] This scientific approach began to emerge in
the 1980s and in 1991, Bailey formulated the expression
“metabolic engineering” to describe the techniques and systems
devised to enhance metabolite synthesis in organisms.[2] The
rationale behind metabolic engineering of natural product
biosynthetic pathways predominantly focusses on enhancing the
synthesis of a required target product that is either insufficiently,
or not naturally, produced by the native host. Establishing new
synthetic routesmay be achieved by manipulating the
endogenous pathway or alternatively by introducing components
of a heterologous pathway[3] designing a range of new enzyme
activities to create products non-native to the host.[4] This
“combinatorial biosynthesis” method involves expressing genes
from various sources in one organism, and has been practised
using the enzymes of plant metabolic pathways for over 30
years.[5] Excellent microbial hosts for metabolic engineering are
Escherichia coli, Saccharomyces cerevisiae and the
Pseudomonas species, because their amenability allows
numerous optimisation approaches using the broad set of
genetic tools available for engineering. Moreover, their fast
growth and prolific protein production means they are able to
produce rich quantities of natural products, especially when
fermented in large cultures [6].
Enhancement of the production of natural products may involve
the import of heterologous enzymes and over-expression of
required native enzymes, increasing the cells‘ uptake of
essential substrates, optimising pathways by minimising
alternative product formation, increasing cofactor availability and
augmenting substrate usage, optimisation of enzyme activity
and specificity by protein engineering or directed evolution, and
optimising access to the final products by secretion or cell lysis
methods.[7] This pipeline is summarised in Figure 1 and
examples of successful methodologies which are typically used
to tackle these aspects including over-expression of enzymes
mediating rate-limiting reactions, introduction of regulatory
transcription factors, heterologous pathway construction,
optimising codons for efficient protein expression and exclusion
of opposing pathways to minimise by-product formation will be
given throughout the review.[2b, 8] Our metabolic engineering
capability has advanced considerably, especially with the
development of novel multivariate modular metabolic
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engineering (MMME) techniques.[9]. The intention of MMME is to
exclude pathway regulatory mechanisms and increase flux
through rate-limiting reactions by assembling a modified
pathway composed of separate modules. Moreover, the ever-
decreasing costs associated with synthesising genes and the
refinement of analytical tools has supported the manipulation of
whole cells, as opposed to simply removing and inserting
individual genes.[7] In the context of natural product biosynthesis,
metabolic engineering has been successfully applied towards
terpenoid, flavonoid, phenylpropanoid, alkaloid and polyketide
pathways, with well documented evidence available in the
literature.[8b, 10]
This review summarises conventional methods and recent
advances in metabolic pathway engineering for the synthesis of
natural products, focusing on how particular strategies have
been applied to enhance isoprenoid, alkaloid, polyketide, and
phenylpropanoid biosynthesis. Although exact approaches are
specific to the natural product in question, general challenges
and metabolic engineering principles are highlighted. We
conclude by contemplating future perspectives and
developments in this progressing research field.
1.1. Importance of metabolic engineering as a tool for
enhanced natural product biosynthesis
Natural products belong to an extensive family of diverse
organic molecules with in excess of 200,000 discovered and
extracted from higher plant species. Plant natural products
comprise of two classes: the primary class, which are ubiquitous
and fundamental for plant viability, such as hormones,
photosynthetic chlorophylls, carotenoids, cytokinins, ubiquinones
and sterols constituting the bilayer.[8a, 11] The secondary class
are significantly more diverse and are named secondary
because they have no established role in growth and
development.[12] The importance of natural products is
emphasised by their significance to the pharmaceutical industry
for over 60 years, delivering novel antibiotics, hormones and
anti-tumour agents to the therapeutic drug repertoire.[6a, 13] Over
the last 25 years, one quarter of pharmaceuticals are isolated
natural products, or designed based on their structure, which is
reflected by their complexity and chirality, a predominant feature
of most approved drugs.[6c, 14] The advantages of plant natural
products to modern society are however diminished by their
relatively poor abundance in nature, restricting their use in
research and development as extraction produces low yields. To
further complicate this problem, the structural complexity of
approved natural product drugs presents challenges for
chemists because synthesis by conventional methods is
impractical and the presence of multiple chiral centres generates
stereoisomers which have to be purified accordingly.[6c] It is
therefore essential that novel approaches are designed to
enhance the accumulation of these valuable molecules that are
naturally synthesised in small amounts.[3]
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oFigure 1. Strategies for the enhancement of natural product production in
microorganisms. (1) Import of heterologous genes to assemble a non-
native biosynthetic pathway in the host organism. (2) Balancing pathway
flux, for example by increasing substrate availability, down regulating
competing pathways, or increasing expression of key pathway enzymes.
(3) Protein engineering to enhance or modify individual pathway
enzymes.
(1) Import of heterologous
genes (3) Protein Engineering
(2) Balancing Pathway Flux
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PV ALMKIADELQ.2. Natural Product Biosynthetic Pathways
espite the vast richness of natural products, they are derived
rom limited primary metabolites and are synthesised by
elatively few central biosynthetic pathways (Figure 2). Briefly,
olyketides and non-ribosomal peptide natural products are
enerated from simple substrates such as acetyl-CoA,
ropionyl-CoA, malonyl-CoA, methylmalonyl-CoA or amino acids
hrough the action of huge PKS or NRPS megasythases. The
itrogenous alkaloids are a diverse class of natural products
sually derived from amino acids such as histidine,
henylalanine, tyrosine, and tryptophan, amongst other
ubstrates such as purines and caffeine.[15] Phenylpropanoids,
omprising of the flavonoids, coumarins, lignans, and stilbenes,
re phenolic natural products comprised of tyrosine and
henylalanine amino acids condensed with malonyl-CoA units.[16]
nd isoprenoid biosynthesis features the terpene synthases
hich cyclise poly-isoprene units to generate over 40000 distinct
soprenoids.[17]
he diversity of natural products in each of these classes is also
ttributed to tailoring enzymes which facilitate glycosylation,
ydroxylation, methylation, halogenation, and reduction
eactions to generate the final unique compounds.[18] Although
atural products display distinctive structural and chemical
haracteristics, similar metabolic engineering strategies may be
mployed to enhance their yield and to provide routes to
ngineer new natural products. We begin by considering
raditional strain improvement methods before discussing
echniques for heterologous biosynthesis and pathway
ptimisation and future perspectives in this research field.
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1.3. Traditional Strain Improvement
In nature, sufficient quantities of secondary metabolites may
only be synthesised when absolutely necessary to confer a
selective advantage.[19] Their relatively low abundance therefore
presents a problem not only with extraction yields, but also with
industrial scale production of the natural organism. Initial
strategies to improve yields involved traditional strain
improvement where native producing strains were screened in
numerous rounds of natural selection for their elevated ability to
synthesise the desired natural product. This is a reasonable
approach when no prior knowledge of the biosynthetic pathway
is known.[19]
Early examples of conventional strain improvement are
demonstrated in the isolation of Penicillium chryogenum; a
penicillin producing strain with titres 100-fold higher than the
original strain isolated by Fleming.[20] Industrial strains are now
predicted to be producing penicillin at exceptional titres with a
100,000-fold enhancement.[20] Although natural penicillin
production represents a successful attempt at strain
improvement, this method can be laborious and time consuming,
with only 1 in 10,000 organisms isolated with each round
selection.[19] With advances in our understanding of metabolic
pathwaysand expansion of our genetic toolkit, enhancement of
natural product yields in native strains is promising. This
technique however is limited, as not all organisms are
fermentable or genetically tractable. Heterologous biosynthesis
and optimisation therefore represents a more successful
approach to improve natural product yields, assuming the
necessary biosynthetic pathway is known.
2. Import of heterologous enzymes and
overexpression of required native enzymes
The significance of plant natural products to human healthcare
have resulted in considerable interest towards their manufacture
in microbial hosts.[10g, 21] Enzyme biocatalysts in microbial
systems have considerable advantages over extraction and
chemical manufacturing, primarily because of their remarkable
selectivity, so their products are enantiomerically distinct, but
also because of their proficiency under mild conditions.[22]
However, our potential to reconstruct metabolic pathways is
limited, not only by our understanding of the biosynthetic route,
the enzymes catalysing these reactions and their regulatory
mechanisms, but also by physical obstacles such as native
expression and functionality of eukaryotic enzymes, and
preventing toxicity in the host due to the build-up of
intermediates.[4, 21a] Heterologous production of plant natural
products in microbes represents two complicated challenges;
firstly, identification of the distributed genes responsible for the
biosynthesis of the desired compound, and secondly achieving
functional expression of large, complex enzymes in lower
organisms.[19] An example of expression difficulties is
demonstrated by the P450 modification enzymes, featuring in
many of the plant natural product biosynthetic pathways.[23]
Although heterologous expression of P450’s in eukaryotes, for
example Saccharomyces, is fully functional, expression in
prokaryotic microorganisms, such as E. coli, is challenging due
to lack of post-translational modifications, inability to translate
this membrane bound enzyme on membranes, and incorrect
protein folding.[24] Moreover, following elucidation of the central
biosynthetic pathways in plants and bacteria, it is necessary to
understand complex regulatory mechanisms.[25] Nevertheless,
natural product biosynthetic pathways have been successfully
translated into heterologous systems, including those encoding
precursors for the significant isoprenoids, paclitaxel and
artemisinin, and the alkaloid precursor reticuline. Assembly of
artificial pathways has also been successful in flavonoid,
phenylalanine and phenylalkaloid biosynthesis, amongst other
natural products.[19]Figure 2. The vast number of natural products are generated from a
surprisingly small number of building blocks from primary metabolism.
The figure illustrates the synthesis of a number of the major families of
natural product.
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possibility of industrial fermentation are advantageous; E. coli
boasts all of these characteristics and is an excellent host for
metabolic engineering. Secondly, the natural product class and
complexity must be evaluated. Natural product pathways in
eukaryotic organisms are more likely to be reconstituted
successfully in eukaryotic hosts, especially since functional gene
expression is favoured. Thirdly, one needs to consider
transformation and metabolic engineering techniques available
to manipulate the chosen host. For example, particular hosts
present technical barriers to introduction of genetic material.
Finally, it is necessary to understand metabolism native to the
chosen heterologous host, not only to assess the hosts
capability to synthesise a compound, but also to anticipate
interplay between metabolic pathways that could complicate
production.[18] These criteria will be further elaborated using
specific examples to demonstrate achievements in heterologous
biosynthesis of natural products.
Isoprenoids are derived from the five-carbon metabolite
precursors, isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMPP), and can be synthesised by two different
metabolic pathways depending on the organism: the mevalonate
(MVA) pathway or the methyl-D-erythritol 4-phosphate/1-deoxy-
D-xylulose 5-phosphate (MEP/DOXP) pathway (Figure 3).[6b, 26]
Optimisation of precursor concentrations either by native
pathway optimisation or transportation of a heterologous
pathway, in combination with heterologous expression of a
specific terpene synthase enzyme is necessary to successfully
produce isoprenoids at relevant concentrations. Efforts to
optimise the endogenous DOXP pathway in E. coli to increase
the supply of isoprenoid precursors required for high-level
production of lycopene have been described.[21d, 27] Simply
overexpressing native DOXP pathway enzymes, or balancing
concentrations of the DOXP pathway substrates, pyruvate and
glyceraldhyde-3-phosphate, has resulted in enhanced lycopene
production.[21d, 27] Similarly, enzymes of the native DOXP
pathway and prenyldiphosphate synthases, catalysing the
synthesis of GPP and GGPP, were overexpressed to increase
the production of monoterpenes and diterpenes.[28] For example,
transforming E. coli with multiple gene operons encoding these
pathway enzymes, provides a system for enhanced production
of terpenoids when coupled with expression of theFigure 3. Biosynthesis of the isoprenoid family of natural products. The
universal isoprenoid precursors, IPP (isopentenyl diphosphate) and
DMPP (dimethylallyl diphosphate), can be synthesised by (I) the MVA
(mevalonate) pathway by conversion form acetyl-CoA involving 6
enzymatic steps or (II) the DOXP (1-deoxy-D-xylulose-5-phosphate)
pathway (also referred to as the MEP pathway) by a 7 enzymatic step
conversion from glyceraldehyde-3-phosphate and pyruvate.
Condensation of IPP and DMPP generate the first intermediate, geranyl
diphosphate (C10), and sequential appendages of IPP create further
intermediates: farnesyl diphosphate (C15) and geranylgeranyl
diphosphate (C20). Downstream enzymes catalyse a range of chemical
modifications to cyclise, oxidise, reduce, isomerise and hydroxylate the
prenyldiphosphate intermediates to generate the respective terpenoid
product.he diverse nature and multi-functional properties of natural
roducts have inspired significant interest in their microbial
actory production and optimisation of their biosynthetic
athways.[6c, 21a-c] Over the past 20 years a substantial number of
etabolic engineering approaches, with emphasis on
eterologous expression, have been applied to various natural
roduct biosynthetic pathways in microbes and plants, to
aximise their synthesis far beyond what is achievable naturally,
nd produce a yield considerably higher than simple extraction.
eciding to use a heterologous biosynthesis approach begins
ith selecting an appropriate chassis in which to express the
athway enzymes. Technical convenience is a highly influencing
actor when considering a heterologous host. Well characterised
rganisms requiring simple culturing techniques, with the
corresponding terpene synthase.[28] Although these approaches
have slightly increased isoprenoid production, one fundamental
aspect limiting higher yields is the endogenous regulation
mechanism present in the E. coli host. In order to maximise
terpene yields, heterologous import of the yeast MVA pathway
needs to be considered.[29] This approach has been successfully
applied to E. coli strains, now capable of functioning as platform
hosts for the production of any terpenoid compound.
Circumventing the native, highly regulated DOXP pathway has
generated considerably higher concentrations of the IPP and
DMPP precursors, so abundant in fact, that the accumulation of
toxic prenyldiphosphate intermediates halts the growth of E. coli.
Overcoming this toxicity is however possible by overexpressing
downstream pathway enzymes, for example amorphadiene
synthase, to relieve toxic intermediate build-up by shuttling
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hFigure 4. Schematic representation of the engineered artemisinic acid biosynthetic pathway in a genetically modified strain of S. cerivisiae. Overexpressed
genes are shown in green. Heterologous expression of the amorphadiene synthase (ADS), amorphadiene oxidase (CYP71AV1), NADPH:cytochrome P450
reductase (CPR1), cytochrome b5 (CYB5) artemisinic aldehyde dehydrogenase (ALDH1) and alcohol dehydrogenase (ADH1) from Artemisia annua resulted in
production of artemisinic acid. Squalene synthase (ERG9) expression was restricted using a methionine repressible promoter (PMET3) to reduce competition for
farnesyl diphosphate. IPP, isopentenyl diphosphate; DMPP, dimethylallyl diphosphate; FPP, farnesyl diphosphate; tHMG1, truncated HMG-CoA reductase;.
ERG10 - acetyl-CoA C-acetyltransferase; ERG13 - hydroxymethylglutaryl-CoA synthase; ERG12 mevalonate kinase; ERG8 - phosphomevalonate kinase;
ERG19 mevalonate diphosphate decarboxylase; ERG20 (encoding yeast farnesyl diphosphate synthase)hrough sequential enzymes.[10a] This aspect has also been used
or α-pinene production, where co-expression of the α-pinene 
ynthase and import of the yeast MVA pathway enzymes has
oosted titres of α-pinene in E. coli to 0.97 g L-1.[30] Similarly,
arnesol production in E. coli is significantly boosted when the
verexpression of farnesyl pyrophosphate synthase (ispA) is
upplemented by supplying higher levels of DMPP and IPP from
he heterologously expressed yeast MVA pathway.[31]
further example of successful natural product production from
eterologous gene expression is the microbial production of the
ntimalarial drug artimisinin (Figure 4).[32] Isolation of this
esquiterpene lactone from the plant sweet wormwood is
nadequate, prompting a microbial engineered manufacturing
pproach.[33] To synthesise the early artemisinin precursor
morphadiene, a codon optimised amorphadiene synthase was
o-expressed in E. coli with the high flux MVA pathway
enes.[10a] Subsequently, expression systems have moved to the
ore functional Saccharomyces as a microbial host, prompting
he expression of the amorphadiene synthase gene in yeast by
hromosomal integration and plasmid transformation
echniques.[34] Further optimisation of the native yeast MVA
athway, along with expression of the P450 enzyme catalysing
he synthesis of artemisinic acid yields high levels of this
ompound that can be used to semi-synthetically derive
rtemisinin.[35] and a breakthrough in rational artemisinin
ynthesis has been demonstrated, where a comprehensive
iosynthetic pathway has been expressed in Saccharomyces to
roduce artemisinic acid, and a feasible process for its chemical
onversion to artemisinin outlined (Figure 4).[36] Although there
as been enormous success in this field, innovative ideas for
metabolic engineering in Bacillus are currently being studied,
optimising the expression of individual pathway operons using
separate promoter elements and balancing inducer
concentrations.[37]
Heterologous expression also plays an important role in the
engineered production of phenylpropanoids including the
flavonoid and stilbene molecule classes (Figure 5). These
products constitute a diverse group of plant secondary
metabolites derived from the condensation of phenylalanine or
tyrosine with numerous malonyl-CoA molecules. Significant
interest has been directed towards microbial synthesis of
phenylpropanoids due to their natural health benefits as
excellent antioxidants with potential as pharmacological agents
with antiviral, antibacterial, anticancer and estrogenic
activities[16a], but prokaryotes do not possess the
phenylpropanoid pathways of plants.[38]
The phenylpropanoid core is synthesised by non-oxidatively
eliminating the amino group by tyrosine ammonia-lyase (TAL) or
phenylalanine ammonia-lyase (PAL), depending on the
incorporated amino acid. Successive modification reactions
mediate reduction, hydroxylation and methylation reactions to
generate the precursors for the subfamilies of the
phenylpropanoids: flavonoids, coumarins, lignans and
stilbenes.[16b] Flavonoids are derived from a universal chalcone
precursor; synthesised by the enzyme chalcone synthase,
condensing one molecule of 4-coumaroyl CoA with three
molecules of malonyl-CoA. Divergent branching pathways
originating from the chalcone precursor are responsible for the
multitude of flavonoid subfamilies.[38] Recombinant
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flavonol 3β-hydroxylase (FLT), dihydroflavonol reductase (DFR) 
and leucocyanidin reductase (LAR) yielded the cathechins,[44]
whilst expression of FLT with flavonol synthase (FLS) yielded
the flavonols.[10e, 45] Moreover, the flavanones have been
generated in E. coli [46] and Saccharomyces [47] by expression of
the essential precursor flavanone pathway genes together with a
flavanone synthase (FNA). Although substantial efforts have
improved yields of various flavonoids, scalable fermentation
methods pose one significant disadvantage; the
supplementation of expensive phenylpropanoic substrates in the
media. Therefore, recent advances in flavonoid microbial
synthesis have focused on engineering an E. coli strain which
has already been optimised for tyrosine production. This strain
directly synthesises tyrosine from glucose, without
supplementation of the amino acid in the medium. With
concomitant expression of CHS and three codon optimised
flavonoid pathway enzymes, TAL, 4CL and CHI, the resultant
strain generated 29 mg/L naringenin,[48] a 64-fold improvement
on the first naringenin producing strain by simply expressing
three pathway enzymes.[41]
Stilbenes are derived via the same central pathway to the
flavonoids, synthesising the universal chalcone precursor
molecule, except shuttling this intermediate through stilbene
synthase (STS) as opposed to chalcone synthase (CHS) for the
flavonoids. An interesting stilbene of particular interest is
resveratrol; a potent antioxidant with potential cancer
chemopreventive properties.[49] Synthesis of resveratrol has
been observed in yeast strains, heterologously expressing PAL,
4CL and STS, with the latter two enzymes expressed as
enzymatic fusions.[50] Protein fusions will be discussed in the
optimisation of pathway flux section, as a method to augment
substrate channeling.
The alkaloids represent another family of natural products where
heterologous expression of enzymes is absolutely necessary forFigure 5. . Biosynthesis of the phenylpropanoids. The phenylpropanoid
core is generated via elimination of the amino group from the aromatic
amino acids tyrosine and phenylalanine by the enzymes tyrosine ammonia
lyase (TAL) and phenylalanine ammonia lyase (PAL), respectively. 4-
coumaroyl-CoA ligase (4CL), chalcone synthase (CHL) and chalcone
isomerase (CHI).henylpropanoid pathways have been reconstituted in E. coli
nd S. cerevisiae, expressing PAL to derive phenylalanine
ased flavonoids,[39] and TAL to derive tyrosine based
lavonoids.[40] This represents an entry point into
henylpropanoid metabolism, providing the appropriate
recursors for the flavonoids and stilbenes. The first production
f flavonoids in E. coli was reported recently, by also expressing
-coumaroyl-CoA ligase (4CL) and chalcone synthase (CHS),
long with PAL, as part of an artificial gene cluster from
treptomyces ceolicolor. When supplied with the appropriate
recursors, tyrosine and phenylalanine, naringenin chalcone, a
yclised intermediate in the flavonoid pathway, and pinocembrin
halcone were synthesised, respectively (Figure 5).[41] Similarly,
ixtures of flavonoid compounds have been reported in yeast,
xpressing similar heterologous enzymes from Rhodosporidium,
rabidopsis and Hypercium plant species.[42] Heterologous
xpression of the successive enzyme in the flavonoid
iosynthetic pathway, chalcone reductase (CHR), generated the
erivative molecules 5-deoxyflavones and 5-hydroxy
lavonones.[43] Expression of further heterologous enzymes,
their synthesis in microbes.[15] Alkaloids, with substantial
pharmacological applications as analgesics, stimulants and
chemotherapeutics, are a family of nitrogenous, low molecular
weight compounds derived from amino acids such as histidine,
phenylalanine, tyrosine and tryptophan, and other substrates
such as purines and caffeine.[16b] Biosynthesis of the
isoquinoline alkaloids involves the essential precursor molecule
S-norcoclaurine, formed by the condensation of dopamine and
4-hydroxyphenyl acetaldehyde (4HPAA) in a reaction catalysed
by norcoclaurine synthase (NCS). S-norcoclaurine is
consequently converted to S-reticuline by four sequential
enzymes; three transferases and a hydroxylase.[10g] Difficulties in
the production of initial intermediates in the benzyl isoquinoline
alkaloid pathway are presented in microbial systems, due to the
tedious expression of eukaryotic P450 mono-oxygenases. Since
this pathway is difficult to reconstruct for efficient product of
benzyl isoquinoline alkaloids, subversion using a microbial
monoamine oxidase simplified the production of reticuline.
Reconstructing the benzyl isoquinoline alkaloid pathway in E.
coli, consisting of the three transferases and hydroxylase
enzymes from Coptis japonica, and monoamine oxidase enzyme
REVIEW
from Micrococcus luteus, yielded a strain producing 55 mg/L S-
reticuline.[10g] Moreover, by integrating enzymatic activities from
different plant species, increasing diversity can be generated in
such alkaloid natural products. This is demonstrated by the
notable work synthesising sanguinarine/berberine and
morphinan subfamilies of the benzyl isoquinoline alkaloids by
assimilating enzymes from three different plants.[10f]
3. Optimising pathway flux
Natural biosynthetic pathways in the native host are regulated by
exact mechanisms, ensuring metabolites are synthesised in
sufficient amounts for cell growth and survival without wasting
important resources on dispensable processes. However,
reprogramming metabolic pathways in heterologous organisms
presents the challenge of reconstructing regulatory control to
mimic endogenous metabolism. Without fundamental control
points, heterologous pathways are excessive, leading to
retardation of growth, accumulation of toxic intermediates and
metabolic imbalance.[51] Deletion of competitive pathways,
creation of protein fusions and scaffolds, optimising cofactor
regeneration and manipulating pathway regulatory elements are
useful methods to optimise pathway flux and maximise natural
product titres.
3.1. Deletion of competing pathways
Understanding the complex metabolism native to the host
organism is essential to assess interplay between metabolic
pathways that could otherwise complicate production to obtain
high yields.[18] Natural endogenous capabilities of the host can
deplete essential precursors, intermediates and cellular
resources if occupying roles in competing pathways. By
eliminating or down-regulating enzymes in major opposing
pathways, the synthesis of desired natural products is favoured
as an alternative to energy depleting by-product formation.[19]
For example, increased production of the sesquiterpenes
farnesol and patchulol[52], and amorphadiene [53] in yeast was
accomplished by replacing the endogenous promoters in the
major opposing pathway enzyme squalene synthase, encoded
by erg9, by the methionine repressible promoter MET3 (Figure
4). Squalene synthase uses the central sesquiterpene
intermediate farnesyl pyrophosphate (FPP), and an optimal
concentration of methionine could be established to inhibit the
activity of squalene synthase sufficiently to increase synthesis of
farnesol, patchulol and amorphadiene without interrupting
essential endogenous processes.[52] More recently a similar
technique has been applied towards α-santalol synthesis, using 
the glucose repressible promoter HXT1 to modulate the
expression of ERG9.[54] A similar problem with supply of
precursors arises for the synthesis of flavonoid and polyketide
natural products where the levels of the precursor malonyl-CoA
naturally present in E. coli is limited.[55] Malonyl-CoA is a central
precursor for many endogenous pathways and inhibition of
competitive malonyl-CoA consuming routes is therefore a
suitable strategy to increase availability. Multiple engineering
methods have been devised to accumulate the malonyl-CoA
substrate for high-level flavanone and anthocyanin production in
E. coli (Figure 6).
A significant (15-fold) enhancement in the cellular pool of
malonyl-CoA has been demonstrated by over-expressing acetyl-
CoA carboxylase (ACC), irreversibly converting acetyl-CoA to
malonyl-CoA, and secondly improving ACC conversion activity
by increasing acetyl-CoA availability. This was achieved by
deleting opposing pathways forming ethanol and acetate by-
products and overexpressing an acetate-forming enzyme. This
modified strain of E. coli with improved cellular concentrations of
malonyl-CoA provides a platform for enhanced production of
natural products, such as flavonoids and polyketides, where
central malonyl-CoA substrates are rate-limiting.[55]
Fatty acid biosynthesis also competes for the supply of malonyl-
CoA and hinders flavonoid production by converting the malonyl-
CoA substrate to acetyl-CoA via fatty acid synthase enzymes.
Following assembly of the heterologous biosynthetic pathways
directing flavanone and anthocyanin synthesis, the intracellular
concentration of the essential metabolite malonyl-CoA was
increased up to 250% by introducing an alternative malonate
assimilation pathway. Inhibition of the competitive fatty acid
synthesis pathway using sub-lethal concentrations of the
antibiotic inhibitor cerulenin enhanced flavonoid production
levels to a remarkable 900%. Using this approach, the yield of
flavonones was reported up to 700 mg/L and anthocyanins up to
113 mg/L, when supplemented with their appropriate
phenylpropanic acid and flavan-3-ol precursors, respectively.
Moreover, the results reinforce the idea that carbon metabolites
are predominantly channelled towards fatty acid biosynthesis,
which is therefore a key competitive pathway in flavonoid
biosynthesis.[56] Integrating multiple pathway optimisation
techniques has also been useful in S. cerevisiae engineering for
α-santalene production; a highly valuable constituent of 
sandalwood oil. The approach previously described, regulating
the expression of ERG9 using the HXT1 glucose sensing
promoter, was firstly applied together with the deletion of two
lipid phosphate phosphatases (LPP) in order to increase
available FPP for α-santalene synthesis. Secondly, two central 
enzymatic reactions catalysed by the tightly controlled FPPS
and HMG-CoA reductase (HMGR) enzymes were optimised, by
deleting the regulatory domain of HMGR and over-expressing
FPPS; this increased the sesquiterpene FPP precursor. Thirdly,
the concentration of the necessary NADPH reductive cofactor
was increased by deletion of an NADPH utilising dehydrogenase
whilst expressing an NADP consuming dehydrogenase,
regenerating NADPH. The final engineering involved the
endogenous MVA pathway, introducing a continuously activated
transcription factor known to be involved in expression of the
corresponding genes.[57]
Expanding the concept of gene deletion presents the idea of
creating a minimal host organism for the synthesis of secondary
metabolites. One can envisage an organism solely committed to
synthesising the desired natural product, void of any
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proximity and to reduce diffusion times.[60] Production of the
diterpene miltiradiene, a Chinese medicine constituent, has also
benefitted from fusion of consecutive pathway enzymes. When
two fusion proteins, one of Salvia mitiorhiza kaurene synthase-
like (SmKSL) and labdadienyl/copalyl diphosphate synthase
(SmCPS) and one of FPP synthase and GGPP synthase, were
expressed together an 8-fold increase in the yield of miltiradiene
was observed (Figure 7A). This fusion of terpenoid synthases
mimics the complex PKS mega-structure.[61] Application of
protein fusion technology has also been demonstrated within the
stilbene class of natural products, creating a 4-coumaroyl-CoA
ligase (4CL) and stilbene synthase (STS) fusion to increase the
synthesis of resveratrol. By channeling intermediates and
ensuring the active sites are in close proximity, the efficiency of
the 4CL:STS enzyme fusion increased by up to 15-fold in yeast.
Although protein fusions have demonstrated potential to
optimise flux through metabolic pathways, they do present some
limitations, dependent on the particular enzymes involved. Firstly,
not all enzymes behave particularly well when fused to another
enzyme in a chimera, for example, enzymes with catalytic
functions residing in the termini are prone to misfolding when
involved in a protein fusion. Secondly, the stoichiometry of the
enzyme fusion is determined by the ability of the tethered
proteins to functionally fold; inability to fold correctly when linked
to multiple enzymes results in protein fusions limited to a 1:1Figure 6. Engineered pathways for increased intracellular malonyl-CoA
concentration as a precursor for flavonoid and polyketide biosynthesis. Two
alternate strategies are shown: (1) In work by Zha et al. intracellular malonyl-
CoA levels were increased by up- (green arrows) and down- (red arrows)
regulating central metabolic enzymes in E.coli to funnel metabolism into
malonyl-CoA production. (2) An alternative strategy used by Leonard et al.
incorporated a malonate assimilation pathway (blue arrows) to allow direct
synthesis of malonyl-CoA. The fatty acid synthase inhibitor cerulenin was
used to downregulate the competing fatty acid pathway.non-essential competing pathways and directing all metabolites
only towards those pathways absolutely required for survival and
natural product biosynthesis. Advanced genome engineering
techniques have facilitated the creation of minimal-genome
E. coli, displaying increased genome stability, improved
transformation efficiency and importantly enhanced production
of biological molecules corresponding to the pathway assembled.
Remarkably, the streamlined E. coli strain with a genome
reduction of 22% not only exhibits the enhanced characteristics
above, but also has no growth deficiency, providing a promising
novel approach to biochemical production.[58]
3.2. Protein Fusions and scaffolds
Although deleting competitive pathways and directing
intermediates towards the desired route rather than an
alternative one is advantageous, optimal efficiency of substrate
usage can be facilitated by using protein fusions (Figure 7). A
versatile technique which can be applied to numerous
biosynthetic pathways; protein fusion combines the enzymes
catalysing sequential reactions in a pathway. This provides
several advantages. The substrate channeling allowed in such
fusion proteins prevents loss to competing enzymes, decreases
intermediate diffusion distance and loss to the environment, and
protects labile intermediates from the solvent.[59] Creation of
multi-enzymatic protein chimeras has been applied to elevate
yields of several natural products. Yields of the sesquiterpene
patchoulol were increased by fusing the sequential enzymes
farnesyl pyrophosphate synthase (FPPS) and patchulol
synthase (PTS) to maintain the required intermediates in close
ratio. Consequently, this ratio may not be optimal for pathway
flux, especially if the corresponding enzymes display different
kinetics.[62] Therefore, novel approaches such as scaffolding are
desirable to alleviate the enzyme requirements for substrate
channeling (Figure 7B). The concept of engineering protein
scaffolds involves creating synthetic complexes of pathway
enzymes to balance metabolic flux and maximise efficiency in
entirely heterologous systems.[63] Although assembly of a
heterologous pathway circumvents endogenous regulatory
mechanisms, flux imbalances are inevitable as the native
regulatory mechanisms are not translated into the system.Figure 7. Substrate channelling using protein fusions and scaffolds.
A. Creation of two fusion proteins, one of FPP synthase (ERG20) and GGPP
synthase (BTS1), and one of kaurene synthase-like(SmKSL) and
labdadienyl/copalyl diphosphate synthase (SmCPS) increased yields of the
diterpene miltiradiene. B. The use of synthetic protein scaffolds can balance
both substrate channelling and enzyme stoichiometry. Scaffolding of
acetoacetyl-CoA thiolase (AtoB), hydroxy-methylglutaryl-CoA synthase
(HMGS) and hydroxymethylglutaryl-CoA reductase (HMGR) in a 1:2:2 ratio
led to a 77-fold increase in mevalonate production.
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Therefore, engineering regulatory control of the introduced
pathway needs to be considered to balance stoichiometry and
minimise accumulation of metabolites that are toxic to the
host.[64] Synthetic protein scaffolds spatially recruit pathway
enzymes by engineering interactions between well-established
protein-protein interaction domains of signalling proteins and
their corresponding ligands. This balances flux through the
metabolic pathway, increasing effective local concentrations of
intermediates, and preventing intermediate loss and toxic
accumulation. Furthermore, the number of interaction domains
between the different enzymes can be modified to create novel
scaffolds with varying numbers of enzymes. Inspired by natural
modular machines, such as polyketide synthases and non-
ribosomal peptide synthases, the scaffolding approach was
applied to three enzymes of the mevalonate pathway, converting
acetyl-CoA to mevalonate. Optimising the stoichiometry of the
reaction using this method achieved a remarkable 77-fold
enhancement in mevalonate, despite lower enzyme expression.
Moreover, this strategy has proved applicable to other
biosynthetic pathways to rapidly optimise and refine metabolic
flux, recruiting specific numbers of enzymes into a functional
complex.[63]
3.3. Cofactor regeneration and optimisation
An important feature of many natural product biosynthetic
pathways is the use of redox cofactors such as NADH and
NADPH by metabolic enzymes. Optimising cofactor availability,
balancing redox potential and accelerating regeneration reduces
the metabolic burden imposed on the system and increases flux
through the metabolic pathway to generate higher yields of
natural products.[51] These features can be established by
engineering pathways to elevate concentrations of highly
required cofactors,[65] or alternatively by modifying or exchanging
key enzymes in the pathway to change their cofactor
preference.[66]
Biosynthetic pathways dependent on NADPH cofactors require
plentiful supply of nicotinamide and careful redox balance for
maximal pathway efficiency.[67] The importance of NADPH
availability is demonstrated in the biosynthesis of the flavonoid
polyphenols, leucoanthocyanidins and (+)-cathechins, since their
corresponding enzymes, dihydroflavonol 4-reductase (DFR) and
leucoanthocyanidin reductase (LAR), are NADPH-dependent.
After identifying the primary restriction factor for the high-level
production of polyphenols as the availability of NADPH, a
stoichiometric-based simulation method was designed where
combinations of different genes were repressed to increase the
intracellular concentration of NADPH. Appropriate combinations
of glycolytic enzyme deletions were designed and constructed in
E. coli to redirect the metabolic flux towards the NADPH
producing pentose phosphate pathway, elevating the
intracellular concentration of the essential redox cofactor. The
optimal strain was a triple mutant deficient in three genes
encoding phospholipase (pldA), phosphoenolpyruvate
carboxylase (ppc), and phosphoglucose isomerase (pgi) to
produce excellent yields of 817 mg/L leucocyanidin and 39 mg/L
(+)-cathechin.[65a]
Exchanging key enzymes in central metabolism that consume
essential cofactors for those that generate them, is another
successful strategy to enhance intracellular NADPH and yields
of natural products that require this specific redox factor during
biosynthesis. Glycolytic metabolism has been engineered in
E. coli to use an NADP-dependent enzyme instead of an
NAD-dependent enzyme, generating NADPH during the
oxidation of glyceraldehyde-3-phosphate to 1, 3-biphospho-
glycerate as opposed to NAD. The efficacy of the engineered
system was evaluated by also introducing lycopene and ε-
caprolactone heterologous pathways, demonstrating higher
productivity than parental strains.[65b] Furthermore, direct intra-
conversion of NADH to NADPH through the expression of a
transhydrolase has enhanced the productivity of an
amorphadiene producing E. coli strain. The engineered strain,
already transformed with the yeast MVA pathway enzymes,
demonstrated a 120% increase in amorphadiene production with
yields of 700 mg/L. This work highlights the importance of
cofactor regeneration in maximising product yields, since the
rate-limiting factor was NADPH availability due to presence of
the high-flux MVA pathway.[66b] Alternative approaches aim to
specifically modify central enzymes in the pathway by screening
cofactor-dependent heterologous enzymes for optimal kinetic
parameters,[66b] or by rational protein engineering to switch
cofactor specificity, manipulate NAPDH metabolism and
regenerate large amounts of the required cofactor.[66a]
3.4. Multivariate-modular pathway engineering
Metabolic engineering approaches have predominantly explored
the optimisation of separate components of biosynthetic
pathways. In the case of isoprenoids it seems rational to simplify
the pathway into an upstream segment, providing the IPP and
DMPP precursors, and a downstream segment, utilising these
substrates to form specific isoprenoids. However, titres have
reached a mere 10 mg/L using this limited approach, simply
overexpressing upstream pathway enzymes and reconstructing
downstream tailoring pathways to direct taxadiene synthesis in
both E. coli and S. cerevisiae.[68] Although reasonable increases
in metabolic flux are observed using this linear model, there are
high-yield limitations such as toxic accumulation of intermediates
and competitive pathways exhausting substrates. A novel
combinatorial approach devised by Ajikumar et al., namely
‘multivariate-modular pathway engineering’ (Figure 8), organises
the biosynthetic pathway into smaller modules, with the
expression of each component fluctuated for optimal synthesis
of taxadiene[6b], an intermediate in the biosynthetic pathway for
the anti-cancer drug taxol.[69] In this example, the expression of
two gene segments – an upstream MEP pathway and a
downstream taxadiene synthesis pathway – were varied
simultaneously to optimally balance the taxadiene synthesis
pathway. In the upstream module, four rate-limiting enzymes
were overexpressed to synthesise an abundant supply of the
IPP and DMPP precursors. In the downstream module, the
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gene segments - an upstream MEP pathway and a downstream taxadiene synthesis pathway – were fluctuated for optimal taxadiene synthesis. In the
upstream module, genes encoding the rate-limiting enzymes (dxs, ispD, ispF and idi) were overexpressed to synthesise an abundant supply of the IPP and
DMPP precursors. In the downstream module, the heterologous enzymes GGPP synthase and taxadiene synthase were expressed to drive the pool of IPP
and DMPP towards taxa-4(5), 11(12)-diene. The upstream and downstream modules were regulated by inducible promoters to allow fine tuning of enzyme
expression. The complete synthesis of taxol from taxadiene involves acylation, benzoylation and oxidations in several enzymatic reactions.eterologous enzymes GGPP synthase and taxadiene synthase
ere expressed to drive the pool of IPP and DMPP towards
axa-4(5),11(12)-diene. The upstream and downstream modules
ere regulated by inducible promoters to allow fine tuning of
nzyme expression. Combinations of various promoters and
ene-copy numbers were analysed to create 32 unique strains,
epresenting a wide range of expression levels. Multivariate-
odular pathway engineering has maximised taxadiene titres in
. coli to gram per litre volumes; an outstanding 15 000 fold
mprovement providing a platform for complete taxol production,
y extracting the intermediate and subsequent further chemical
odification.[6b]
.5. Manipulating regulatory pathway elements
econstructing regulatory control to mimic natural metabolism is
omplemented by relieving endogenous control to optimise flux
hrough the biosynthetic pathway. Engineers, however, must be
areful to relieve control in such a way to enhance metabolism
hrough the chosen pathway without disrupting central
ndogenous metabolism that could otherwise be detrimental to
the host. An approaches which has been applied to
sesquiterpene synthesis and also acts as a platform for the
increased synthesis of other isoprenoids is relieving control
mechanisms of the pyruvate dehydrogenase complex in S.
cerevisiae. The pyruvate dehydrogenase complex creates a
restriction on acetyl-CoA production, the precursor for isoprenoid
IPP and DMPP substrates. Regulatory feedback control
mechanisms were circumvented by introducing heterologous
dehydrogenase and synthetase enzymes to by-pass the
endogenous multi-enzyme complex. Conversion of pyruvate to
acetyl-CoA was enhanced to obtain higher sesquiterpene yields
and created a generalised system for production of other
isoprenoids.[70] Attention has been drawn towards another
essential regulatory step in the endogenous DOXP pathway
mediated by HMG-CoA reductase (HMGR), controlling the levels
of IPP and DMPP. A collection of variant HMGR enzymes were
selected, expressed in E. coli, and their ability in amorphadiene
synthesis assayed. Subsequently, highly performing enzymes
were supplemented with their required redox cofactor, in this
case NADH, to maximise amorphadiene production.[71]
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Further examples of manipulating endogenous metabolism are
demonstrated in phenylalanine synthesis. Phenylalanine and its
hydroxylated derivative tyrosine are fundamental precursors for
natural products such as flavonoids, alkaloids and non-
ribosomal peptides. However, complex intrinsic feedback
mechanisms prevent high-level accumulation of phenylalanine
and tyrosine via the shikimate pathway.[72] Supplementation is
therefore required in the media for their use in natural product
biosynthetic pathways, making fermentation protocols
expensive.[48] Consequently, research into developing an
economical and efficient microbial system is desirable.
Traditional methods have concentrated on eliminating the
negative feedback mechanisms and facilitating carbon flux
through the shikimate pathway.[73] Accumulation of
phenylalanine is prevented by the feedback mechanisms of 3-
deoxy-D-arabino-heptulosonate-7-phosphate synthase (AroG),
chorismate mutase-prephenate dehydrogenase (TyrA), and
transcriptional attenuation of the tyrosine repressor (TyrR).[72]
Limited success has been observed by expressing feed-back
inhibition resistant homologs of AroG and TyrA enzymes in
combination with TyrR deletion, yielding tyrosine concentrations
of 3.8 g/L. Additional engineering in this E. coli strain to enhance
erythrose-4-phosphate (E4P) and phosphoenolpyruvate (PEP)
substrates of the shikimate pathway, expressing ppsA and tktA
genes, has only elevated titres to 9.2 g/L.[73a] However, recent
advancements in tyrosine production have been described,
alleviating shikimate pathway feedback inhibition to engineer an
E. coli strain capable of accumulating significantly higher titres of
401 mg/L tyrosine. This approach effectively creates a
phenylalanine sink, continuously draining phenylalanine from the
system for synthesis of tyrosine, mediated by the enzyme
phenylalanine 4-hydroxylase (PH4). Assuming that
phenylalanine is constantly depleted, the negative feedback
inhibition mechanisms of AroG, TyrA and TyrR are not
repressed, relieving the shikimate pathway from inhibition and
resulting in constitutive tyrosine accumulation.[74]
Outstanding yields of tyrosine have been observed in an E. coli
strain using modular engineering techniques of multiple genes,
maximising production to 80% of the potential yield. Proteomics
and metabolomics aided the design of a modular system
composed of two plasmids synthesising tyrosine from E4P and
PEP. Three major bottlenecks in the shikimate pathway were
identified and alleviated by optimising gene codons, plasmid
copy numbers and promoter activity, and assembling synthetic
operons, including homologs of bottleneck enzymes.
Remarkable tyrosine titres of more than 2 g/L were reported,
demonstrating once again the success of modular pathway
engineering techniques to optimise natural product titres.[75]
4. Pathway optimisation by protein
engineering
Despite progress in metabolic engineering strategies and
synthetic biology in recent years, optimisation of engineered
pathways to reach industrially relevant yields of product
molecules is not trivial. As discussed above, modulating the
expression levels of individual pathway enzymes through
various approaches is a proven strategy for increasing synthetic
pathway efficiency and product titre. However, these strategies
fail to address inefficiencies associated with the individual
pathway enzymes themselves. These inherent enzyme
characteristics can result in bottlenecks, generate
toxic/undesirable by-products, and ultimately reduce titres. It
may, therefore, be desirable to engineer the properties of
pathway enzymes to increase activity, stability, and modify
substrate/product specificity. Furthermore, control of
substrate/product inhibition and protein localisation can be
engineered into individual enzymes to optimise overall pathway
flux. Advances in protein engineering have resulted in notable
improvements in the catalytic efficiency of existing enzymes for
natural or novel substrates, and have even been applied to the
generation of completely novel enzymes. Protein engineering, in
combination with metabolic engineering approaches, is a
powerful tool for the optimisation of synthetic pathways for
secondary metabolite production.
4.1. Optimising catalytic efficiency
Several engineering methods have been developed that target
transcription and translation to balance protein expression and,
consequently, pathway flux. However, in systems with inherently
inefficient enzymes, a concomitant increase in energy and
resource expenditure can be a significant metabolic burden on
the host cell, stifling optimal yields. One approach to increase
the in vivo activities of enzymes in synthetic pathways is to
increase specific activities under the required production
conditions. In one example, the geranylgeranyl diphosphate
(GGPP) synthase enzyme from the hyperthermophile
Archaeoglobus fulgidus was engineered for optimal activity at
ambient temperatures by directed evolution. Selected variants
were identified that increased production of the astaxanthin
precursor lycopene by 100%[76]. Additionally, production of
levopimaradiene, the diterpenoid precursor to the
pharmaceutically important ginkgolides, was improved markedly
by site saturation mutagenesis of synthase enzymes. This
resulted in increased levopimaradiene yield by 2600-fold using
engineered GGPP synthase and levopimaradiene synthase in
an optimised system.[77]
In some cases the in vivo activity of enzymes can also be
improved by increasing the stability and thus proportion of
functional protein expression, by avoiding the accumulation of
inactive insoluble aggregates when over-expressed in
heterologous host systems. This strategy was effectively applied
to improve the in vivo properties of the Abies grandis
γ-humulene synthase (HUM) when expressed in E.coli. An
adaptive evolution model was used to analyse the sequences of
over 30,000 homologs to over 200 E.coli enzymes involved in
central metabolism and the design principles were then used to
redesign the in vivo properties of humulene synthase to relieve
pathway bottlenecks while leaving product distribution
unaltered.[78]
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4.2. Expanding substrate scope
Unlike their counterparts in central metabolic pathways, many
enzymes utilised in secondary metabolism display broad
substrate and product specificities. For example, many
isoprenoid biosynthetic enzymes are known to accept a variety
of both natural and unnatural substrates. Several examples exist
that can synthesise a large range of compounds (>50 in some
cases) from a single substrate. Control of specificity is generally
through a small number of highly stringent enzymes upstream in
the pathway that dictate backbone structures.
The tolerant nature of the terpene synthase active site presents
engineering opportunities, modifying the enzyme structure to
either synthesise different products or provide a preference for a
desired product (Figure 9). For example, the various terpenoid
products of the 5-epi-aristolochene synthase can be changed by
mutating the less conserved residues present in the active site
of the enzyme.[79] Moreover, preference for specific terpenoid
products has been artificially engineered in the promiscuous γ-
humulene synthase, biasing the reaction towards a selection of
the 50 possible sesquiterpene products.[80] The proportion of
terpenoid products can also be adjusted by mutating the metal
ion cofactor binding residues in terpene synthases; as has been
demonstrated for the trichodiene synthase from Fusarium
sporotrichioides.[81] Rational engineering of terpene synthases
represents an interesting approach to bias the formation of
desired terpenes from single substrate compounds.
Several examples of engineered enzymes for the synthesis of
carotenoids, natural pigments with interesting biological
properties, have been reported. In the C40 carotenoid pathway,
phytoene desaturase (CrtI) from Erwinia uredovora and
lycopene cyclase (CrtY) from Erwinia herbicola were evolved by
DNA shuffling to produce C40 carotenoids of higher and lower
levels of saturation, respectively. The discovery of specific CrtI
and CrtY mutants led to a novel biosynthetic route for production
of the cyclic carotenoid torulene in E.coli.[82] In other work, the
C30 carotene synthase, CrtM, from Staphylococcus aureus was
engineered using a combination of directed evolution and
site-directed mutagenesis to synthesise novel longer chain
carotenoid backbones than previously found in nature.[83]
Cytochrome P450 monooxygenases (CYPs or P450s) catalyse
a range of transformations including hydroxylation, epoxidation,
dealkylation at unactivated carbons in a regioselective andFigure 9. Engineering of the promiscuous γ-humulene synthase to show a preference for different cyclisation products. The substrate, farnesyl diphosphate,
binds to the enzyme active site via a metal ion cofactor followed by cleavage of the diphosphate to yield either the trans- or cis- farnesyl cation. From here,
a range of possible cyclisation or deprotonation reactions can occur to generate the final product(s). Yoshikuni et al. identified a range of mutations (shown)
that alter product distributions to give enzyme variants that show a clear preference for each of the compounds shown.
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stereoselective manner and are involved in a range of
biosynthetic routes to useful natural products, generating a great
deal of interest in their use and engineering for use in novel
synthetic pathways. The most prominent examples of the use of
P450s in metabolic engineering are the use of CYP71AV1 from
A. annua, to catalyse three successive oxidation steps in the
conversion of amorpha-4,11-diene to artemisinic acid;[35] and the
use of a P450 enzyme from the Taxus species to catalyse the
regioselective hydroxylation of taxadiene to taxadien-5a-ol in the
synthesis of paclitaxel.[6b] Protein engineering has been
extensively applied to the cytochrome P450 class of enzymes,
making an extensive discussion on the subject beyond the
scope of this review (see [84] and references therein). The
apparent evolvability of P450 enzymes, demonstrated by the
engineering of P450 BM3 from Bacillusmegaterium to catalyse a
range of activities on an impressive range of substrates. Despite
numerous successes in P450 engineering, examples of uses of
engineered enzymes in metabolic pathways remains relatively
rare, likely due to the additional challenges associated with
optimal performance in vivo.
4.3. Bypassing feedback inhibition
As an alternative to engineering the kinetic parameters of
pathway enzymes, flux through a pathway can be increased via
the elimination of feedback regulation by substrates or products.
For example, Liao and co-workers have engineered a novel
pathway for the production of a range of long-chain alcohols –
potential biofuel candidates – from keto-acid intermediates
generated by native amino-acid biosynthesis.[85] Due to the
highly regulated nature of amino-acid metabolism, a key hurdle
to overcome to boost product titres was the relief of feedback
inhibition in these pathways. Introduction of a previously
identified feedback resistant mutant of the aspartate
kinase/homoserine dehydrogenase enzyme (ThrA), which
catalyses the first two steps in the conversion of aspartate to
threonine, resulted in a nearly 4-fold higher titre of 1-propanol
and 1-butanol.[86] In further work on the production of 3-methyl-1-
butanol, incorporation of a feedback resistant mutant of the 2-
isopropylmalate synthase (IMPS) resulted in an 8-fold increase
in accumulation of intermediate 2-ketoisocaproate and
enhanced production of the target product.[87]
Feedback inhibition can be also be eliminated by removing
entire regulatory domains of bottleneck enzymes, as
demonstrated for the optimisation of L-phenylalanine production
in E.coli. In this pathway the key pathway enzyme chorismate
mutase-prephenate dehydratase (CM-PDT) is allosterically
inhibited by binding of the product L-phenylalanine. The E.coli
CM-PDT enzyme contains three distinct domains; CM (residues
1–109), PDT (residues 101–285), and the regulatory-domain
(residues 286–386). Therefore, to overcome the problem of
feedback inhibition a truncated mutant CM-PDT lacking the
entire regulatory domain was created. After further optimisation
of the CM-PDT truncation mutant by directed evolution, a
L-phenylalanine yield of 0.21 g/g glucose could be achieved –
38% of the theoretical maximum yield.[88]
4.4 De novo enzyme generation
In recent years computational design has become a powerful
tool for the generation of tailor-made enzymes that catalyse
unnatural reactions, exemplified by designed enzymes with
retro-aldol, Kemp elimination, and Diels-Alderase activities.[89]
These in silico designed enzymes are capable of impressive rate
enhancements of up to 2 × 105 over the uncatalysed
reaction.[89b] Moreover, directed evolution studies have indicated
that the evolvability of enzymes generated using computational
design methods appears to be high, with further rate
enhancements of over 2000-fold appearing typical.[90] Not only
does this strategy hold a great deal of promise for the rational
design of de novo enzymes to perform novel chemical
transformations, but also opens the door for the engineering of
entire pathways not found in nature. In an exciting
demonstration of the potential of this combinatorial approach, an
enzyme, formolase, was designed to catalyse the carboligation
of three one-carbon formaldehyde molecules into one
three-carbon dihydroxyacetone molecule. Combining the
designed enzyme with those from natural organisms allowed the
construction of a novel carbon fixation pathway, designated the
formolase pathway, converting formate into the central
metabolite dihydroxyacetone phosphate in vitro.[91]
5. Summary and Outlook
The engineering of microorganisms into whole-cell factories for
the synthesis of useful secondary metabolites is of great interest
to chemists and biologists alike. Recent advances in the field
have demonstrated the power of metabolic engineering and
synthetic biology as tools towards acheiving these goals.
Moreover, the complementary fields of metabolic engineering
and protein engineering present the imminent prospect of
expanding the range of metabolites beyond the repertoire of
Nature. As an emerging discipline, one may expect that many
challenges remain before widespread use of engineered
microorganisms for synthesis of complex molecules. Progess is
likely to be facilitated by developments in host organism
optimisation, exmplified by the efforts towards standardised
hosts with minimal genomes and well characterised properties.
Furthermore, advances in efforts to standardise pathway
components and assembly methods via synthetic biology should
speed up novel pathway development significantly. Finally,
development of protein engineering strategies in the context of
metabolic pathways in vivo should augment the progess towards
development of high-yielding pathways and novel natural
products.
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